Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study identifies novel proteomic and metabolomic biomarkers linked to cardiac dysfunction and remodeling in breast cancer patients treated with cardiotoxic therapies, revealing potential pathways for early detection and intervention.
Anti-PD-1 antibody exacerbates pressure overload-induced heart failure by promoting CXCR3+ CD8+ T cell infiltration, which impairs cardiomyocyte mitochondrial function via granzyme B and perforin. This study identifies a novel immunopathoge
Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-ter
A breakthrough study reveals that osimertinib-induced cardiac dysfunction is driven by reversible sarcomere disarray via the GATA4-MYLK3-MYL2 signaling axis, suggesting that myosin activators could mitigate heart failure risk in lung cancer
A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Tri
The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial st